Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2008 (Q1 2008)
Filing Date: April 24, 2008
Alcon operates globally in the ophthalmic market through two segments: Alcon United States and Alcon International. The company markets pharmaceuticals, surgical equipment/devices, and consumer eye care products.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2008 | Q1 2007 |
|---|---|---|
| Sales (Revenue) | $1,536.4 | $1,322.7 |
| Gross Profit | $1,138.1 | $973.7 |
| Gross Margin | 74.1% | 73.6% |
| Operating Income | $500.1 | $403.1 |
| Net Earnings | $429.4 | $346.2 |
| Diluted EPS | $1.43 | $1.14 |
| Operating Cash Flow | $398.1 | $342.9 |
| Cash and Cash Equivalents (End of Period) | $2,499.7 | $1,496.2 |
| Total Debt (Short-term + Long-term) | $1,854.5 | N/A |
| Shareholders' Equity | $3,931.1 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 16.2% year-over-year. Excluding foreign exchange effects, constant currency sales grew 9.4%, driven by volume growth in pharmaceuticals, surgical products, and consumer eye care.
- Profitability: Net earnings rose 24.0% to $429.4 million. This improvement was significantly aided by the absence of $32.7 million in impairment charges related to refractive assets that impacted Q1 2007 results.
- Segment Performance:
- United States: Sales up 5.9%; Operating income up 7.8%.
- International: Sales up 25.6% (12.6% constant currency); Operating income up 21.4%.
- Product Highlights:
- Pharmaceuticals: Vigamox sales up 16.9%; NEVANAC sales up 49.0%.
- Surgical: Intraocular lens sales up 23.6%, driven by premium AcrySof IQ and ReSTOR lenses. Refractive sales surged 160.8% due to the inclusion of WaveLight AG (acquired Nov 2007).
- Expenses: R&D expenses increased 8.5% to $144.9 million. Amortization of intangibles decreased to $8.9 million from $20.0 million in 2007, largely due to the prior year's impairment charges.
Guidance, Outlook, Risks, and Unusual Items
Subsequent Event: Nestlé-Novartis Agreement
On April 7, 2008, Nestlé and Novartis AG announced an agreement for Novartis to purchase approximately 74 million Alcon shares from Nestlé at $143.18 per share. Novartis will hold a minority stake (~25%), while Nestlé remains the majority shareholder (~52%). The agreement includes put and call options for the remaining Nestlé shares exercisable between 2010 and 2011.
Share Repurchases and Dividends
- Repurchases: In March 2008, Alcon halted open market share repurchases under all programs (except for tax withholding on employee awards) pending a board review following the Novartis agreement.
- Dividend: The Board proposed a dividend of CHF 2.63 per share (approx. $2.64), totaling an estimated $790 million, subject to shareholder approval on May 6, 2008.
Risks and Contingencies
- Patent Litigation: Alcon is engaged in patent infringement suits against generic manufacturers (Teva, Apotex, Barr) regarding Vigamox and Patanol. A trial regarding the Alcon patent for Vigamox concluded in March 2008, with judgment expected in H1 2009. A loss could significantly impact sales and profits.
- Antitrust Lawsuit: Synergetics USA filed a civil antitrust lawsuit in April 2008 alleging monopoly power in vitreoretinal surgical equipment, seeking over $100 million. Alcon intends to vigorously defend the case.
- Market Risks: Significant exposure to foreign currency fluctuations and interest rate changes on floating-rate debt.
Investor Verification Checklist
- Novartis Transaction Status: Verify regulatory approval progress for the Nestlé-Novartis share sale and the potential impact on future corporate strategy.
- Patent Litigation Outcomes: Monitor the judgment in the Teva vs. Alcon Vigamox patent case (expected H1 2009) and the status of Apotex/Barr Patanol litigation.
- Dividend Approval: Confirm shareholder approval of the proposed $790 million dividend at the May 6, 2008 annual meeting.
- Share Repurchase Policy: Watch for updates on the resumption or modification of share buyback programs following the board review.
- WaveLight Integration: Assess the ongoing financial impact and integration costs of the WaveLight AG acquisition on future margins.